The evidence behind the OMS Recovery Program is strong and consistent across the medical literature, including:
Evidence supports a paradigm of MS pathogenesis in line with Dr. Corthals’s theory of lipid dysregulation resulting in immune activation and inflammation, with the development of central nervous system lesions leading to progressive disability.
Basic science research has consistently shown MS to be an immune-based disorder; genetic studies of populations with MS show that genes related to immune disorders and vitamin D are at the heart of MS development. Lipid profiles in blood and cell membranes have also been shown to be abnormally biased toward saturated fats in people with MS, with worse disease courses linked to higher levels of cholesterol and saturated fat.
Population studies have shown that MS is more prevalent and progressive:
Meanwhile, MS is less prevalent in populations that:
Quality of life is enhanced – and depression and fatigue are reduced – in parallel with modification of these risk factors. People with MS taking a proactive approach to their own health are healthier and less disabled, with better quality of life and less depression and fatigue.
There is a need for more rigorous controlled clinical studies in the area, but current research supporting the OMS Recovery Program is strong and congruent across a variety of medical literature and research types. Clinicians should have no hesitation in recommending this approach to their patients.